Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jan 27, 2020; 12(1): 10-20
Published online Jan 27, 2020. doi: 10.4254/wjh.v12.i1.10
Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy
Fiona Chautant, Maeva Guillaume, Marie-Angèle Robic, Jean-François Cadranel, Jean-Marie Peron, Hortensia Lison, Charlène Cool, Christophe Bureau, Véronique Duhalde
Fiona Chautant, Service Pharmacie, Centre Hospitalier Universitaire de Toulouse, Hôpital Paule de Viguier, Toulouse 31059, France
Maeva Guillaume, Marie-Angèle Robic, Jean-Marie Peron, Christophe Bureau, Department of Hepato-Gastroenterology, University Hospital, Toulouse 31059, France
Jean-François Cadranel, Hortensia Lison, Department of Hepato-Gastroenterology, Laennec Hospital, Creil 60109, France
Charlène Cool, Department of Pharmacy and UMR INSERM 1027, University Hospital, Toulouse 31059, France
Véronique Duhalde, Department of Pharmacy, University Hospital Toulouse, Toulouse 31059, France
Author contributions: Chautant F was the guarantor of the article; Chautant F, Bureau C and Duhalde V designed the research study; all authors were involved with data collection or analysis; all authors were involved with data interpretation, drafting or offering critical revisions; Bureau C and Chautant F performed statistical analyses; all authors have read and approved the final manuscript.
Institutional review board statement: As a retrospective study, the approval of the ethics committee was not mandatory (i.e., according to the Jardé Law in France).
Informed consent statement: Informed consent was not required for this study. The data were collected anonymously.
Conflict-of-interest statement: Bureau C and Cadranel JF have conflicts of interest with Alpha Wassermann as speakers at a symposium and Norgine as consultants. The remaining authors disclose no conflict.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Fiona Chautant, PhD, Pharmacist, Department of Pharmacy, University Hospital, 330 avenue de Grande Bretagne, Toulouse 31059, France.
Received: July 1, 2019
Peer-review started: July 1, 2019
First decision: August 7, 2019
Revised: September 30, 2019
Accepted: December 8, 2019
Article in press: December 8, 2019
Published online: January 27, 2020
Core Tip

Core tip: The clinical and economic burdens of hepatic encephalopathy (HE) are tremendous and growing worldwide. Therapies to improve the quality of life of patients and to decrease the rate of hospitalizations and economic consequences are needed. Rifaximin was proved effective to reduce the risk of HE recurrence in patients with episodic forms. However, real-life data are still scarce, particularly concerning persistent HE. In this real-life experience, the effectiveness of rifaximin was confirmed in the prevention of HE episodes recurrence but was not proved in the management of persistent HE.